James B. Tananbaum
CIK: 0001581754
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (21 total)
- Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect3.1M shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect445.3K shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect1.1M shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect742.2K shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Purchase(P)Indirect140K shares at avg. $18.00$2.5M - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect195.8K shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect296.9K shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect3.1M shares- - Apr 1, 2026ALMS
ALUMIS INC.
Other(J)Indirect1.2M shares- - Apr 1, 2026ALMS
ALUMIS INC.
Other(J)Indirect1.1M shares- - Apr 1, 2026ALMS
ALUMIS INC.
Other(J)Indirect1.1M shares- - Apr 1, 2026ALMS
ALUMIS INC.
Other(J)Indirect680.5K shares- - Jan 8, 2026ALMS
ALUMIS INC.
Purchase(P)Indirect294.1K shares at avg. $17.00$5.0M - Jan 8, 2026ALMS
ALUMIS INC.
Purchase(P)Indirect117.6K shares at avg. $17.00$2.0M - Nov 21, 2025ALMS
ALUMIS INC.
Purchase(P)Indirect72.2K shares at avg. $7.38$533K - Nov 19, 2025ALMS
ALUMIS INC.
Purchase(P)Indirect190.5K shares at avg. $6.56$1.2M - Nov 18, 2025ALMS
ALUMIS INC.
Purchase(P)Indirect117.4K shares at avg. $6.19$727K - Nov 17, 2025ALMS
ALUMIS INC.
Purchase(P)Indirect50K shares at avg. $5.60$280K - Nov 17, 2025ALMS
ALUMIS INC.
Purchase(P)Indirect150K shares at avg. $5.59$839K - May 6, 2025ALMS
ALUMIS INC.
Purchase(P)Indirect20K shares at avg. $4.34$87K - May 2, 2025ALMS
ALUMIS INC.
Purchase(P)Indirect25K shares at avg. $4.62$116K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 10, 2026 |  LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 3,117,664 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 445,320 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 1,125,823 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 742,201 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Purchase(P) | 140,000 | $18.00 | $2,520,000 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 195,776 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 296,880 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 3,117,664 | - | $0 | Indirect |
| Apr 1, 2026 |  ALMS ALUMIS INC. | Other(J) | 1,176,470 | - | $0 | Indirect |
| Apr 1, 2026 | ALMS ALUMIS INC. | Other(J) | 1,123,337 | - | $0 | Indirect |
| Apr 1, 2026 | ALMS ALUMIS INC. | Other(J) | 1,123,337 | - | $0 | Indirect |
| Apr 1, 2026 | ALMS ALUMIS INC. | Other(J) | 680,486 | - | $0 | Indirect |
| Jan 8, 2026 | ALMS ALUMIS INC. | Purchase(P) | 294,117 | $17.00 | $4,999,989 | Indirect |
| Jan 8, 2026 | ALMS ALUMIS INC. | Purchase(P) | 117,647 | $17.00 | $1,999,999 | Indirect |
| Nov 21, 2025 | ALMS ALUMIS INC. | Purchase(P) | 72,212 | $7.38 | $532,925 | Indirect |
| Nov 19, 2025 | ALMS ALUMIS INC. | Purchase(P) | 190,500 | $6.56 | $1,249,680 | Indirect |
| Nov 18, 2025 | ALMS ALUMIS INC. | Purchase(P) | 117,374 | $6.19 | $726,545 | Indirect |
| Nov 17, 2025 | ALMS ALUMIS INC. | Purchase(P) | 50,000 | $5.60 | $280,000 | Indirect |
| Nov 17, 2025 | ALMS ALUMIS INC. | Purchase(P) | 150,000 | $5.59 | $838,500 | Indirect |
| May 6, 2025 | ALMS ALUMIS INC. | Purchase(P) | 20,000 | $4.34 | $86,800 | Indirect |
| May 2, 2025 | ALMS ALUMIS INC. | Purchase(P) | 25,000 | $4.62 | $115,500 | Indirect |
1-21 of 21 transactions
About Tananbaum James B.
Tananbaum James B. (SEC CIK 0001581754) files insider reports with the SEC as Director of Latigo Biotherapeutics, Inc. (LTGO) and Director of ALUMIS INC. (ALMS).
Signal8 holds 7 ownership filings by Tananbaum James B. (1 Form 3, 6 Form 4), filed between May 6, 2025 and Aug 10, 2026. Those filings report 21 transactions, from May 2, 2025 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Tananbaum James B.'s filings is in THOUSAND OAKS, CA.
Recent filings by Tananbaum James B.
- Aug 10, 2026: Conversions of LTGO shares (4 lines, Form 4, code C).
- Aug 10, 2026: Open-market purchase of LTGO shares (Form 4, code P).
- Aug 10, 2026: Conversions of LTGO shares (3 lines, Form 4, code C).
- Apr 1, 2026: Other transactions of ALMS shares (4 lines, Form 4, code J).
- Jan 8, 2026: Open-market purchases of ALMS shares (2 lines, Form 4, code P).
Other insiders filing for Latigo Biotherapeutics, Inc. (LTGO)
- 5AM Ventures VI, L.P., 10% Owner
- Sanofi, 10% Owner
- Westlake BioPartners Fund I, L.P., 10% Owner
- Foresite Capital Management V, LLC, 10% Owner
- SMITH TODD N, Director
- SEIDENBERG BETH C, Director